The Utility and Potential of Comprehensive Genomic Profiling

2020年11月2日

In this educational video, Dr. David Eberhard, Senior Medical Director in Oncology at Illumina, explains what comprehensive genomic profiling (CGP) is and how it provides cancer patients and oncologists with a powerful testing approach to help identify biomarkers for therapy selection and eligibility for clinical trials. In addition, he discusses how CGP brings many benefits to a pathology lab, and is the most effective approach for biomarker profiling in a world where new cancer therapy biomarkers are being developed at a rapid pace.

Learn more about the future in Oncology: emea.illumina.com/areas-of-interest/cancer/future-of-ngs-in-oncology.html

Subscribe to the Illumina video channel youtube.com/subscription_center?add_user=IlluminaInc

A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.

*Data calculations on file. Illumina, Inc., 2015.

View customer spotlight videos
youtube.com/playlist?list=PLKRu7cmBQlajfheLzgbI4S7xBn7IDbt79

View Illumina webinars
youtube.com/playlist?list=PLKRu7cmBQlahpXlnrrXlQw9itVJ8yHwUZ

View Illumina product videos
youtube.com/playlist?list=PLKRu7cmBQlaj6YuZmkfxZcT9twqDgP2Xd

View Illumina support videos
youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvM

分享这篇文章